Study design and participants
human immunodeficiency virus
HEPATITIS B, HUMAN IMMUNODEFICIENCY VIRUS
This open-label, single-center trial was conducted at the Radboud University Medical Center (Radboudumc) in Nijmegen, the Netherlands, between April 2019 and February 2021. The study population was comprised of healthy, malaria-naïve, adults aged 18–35 years old at time of first immunization. Upon informed consent, participants were screened for medical and family history, physical examination, complete blood counts, clinical chemistry, and serologic analysis for human immunodeficiency virus, active hepatitis B and C, and asexual 